NFX 88Neurofix - Biotechnology CompanyNeurofix is a biotechnology company founded
by experienced scientists and executives.
Our pipeline consists of products both at
clinical and pre-clinicar development stages.
Invest in biotechnology
neurofix Biotechnology CompanyLipid-based therapies for the
treatment or neurological pathologies

INVESTS IN THE PIONEER SPANISH DRUG AGAINST NEUROPATHIC PAIN CAUSED BY SPINAL CORD INJURY

Neurofix Pharma has just opened a round of financing to complete the clinical study of NFX88, the pioneer drug ‘made in Spain’ that offers hope for patients with spinal cord injury suffering from neuropathic pain.

What is Neurofix Pharma?

Neurofix Pharma is a Spanish biotechnology company that develops a drug to alleviate the pain suffered by people with spinal cord injuries and improve their quality of life. This drug, NFX88, is in the final stages of the IIA clinical trial and represents a pioneering alternative to fill the gap in current treatments.

Since its birth in 2015, Neurofix Pharma has received the support and recognition of various institutions to advance its clinical program. Obtaining seals such as ‘Best NEOTEC line Company’, ‘Innovative SME’ and ‘Excellence of the EU Horizon 2020’, in addition to the support of Enisa, Iberaval, ICO and European SME, among others, stands out. The company also has important investors, among which the Family Office of the Matutes family stands out.

It should also be noted that to complete phase IIA, aid has been co-financed by the European Regional Development Fund with the aim of promoting research, technological development and innovation for an amount of €117,214.81 through the call for grants from the Institute for Business Competitiveness of Castilla y León, in line 2018 R&D PROJECTS. Project title: Research and development to complete a phase IIA and development of a phase IIB/III clinical protocol with NFX88 for the treatment of neuropathic pain in patients with spinal cord injury (File No.: 04/18/sa/0222).

Product under development

The progress of the clinical trial of NFX88 has allowed the integration of Neurofix in the training program Pre-Market Environment (EpM), of Bolsas y Mercados Españoles (BME), as a previous step to the company’s jump to the capital markets. Neurofix has achieved the support of public bodies such as CDTI, ENISA, ICO, IBERAVAL or ICE (Institute for Business Competitiveness, of the Junta de Castilla y León).

NFX 88, a modified oleic acid molecule anti-inflammatory drug with GPCR-G protein uncoupling activity.The effects of NFX88 on hyperalgesia reduction, which is a common condition in neurological disorders and neurodegenerative diseases, will be studied. NFX88 is formulated for convenient oral administration. NFX88 is formulated for convenient oral administration. A Phase IIA clinical trial for neuropathic pain in patients with spinal cord injury has been completed with excellent results

NFX 88

ROAD TO MARKET: EPM – BME GROWTH

PIPELINE

NFX 88 - Neuropathic pain (SCI)

Join Neurofix Pharma

Do you want to join the Spanish company developing the first drug for neuropathic pain in spinal cord injury patients? Hemos ya finalizado la Fase IIA y cada vez estamos más cerca de una realidad que cambiará el mundo.

Get to know us and invest in science and research made in Spain by our side.

DO YOU NEED INFORMATION? WE CONTACT YOU

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.
No hemos podido validar su suscripción.
Se ha realizado su suscripción.
NEWSLETTER DE NEUROFIX PHARMA
Acepto las condiciones legales y recibir sus newsletters.
sucribirse

Actualidad Neurofix